The Rate of Conversion from Immune-tolerant Phase to Early Immune-clearance Phase in Children with Chronic Hepatitis B Virus Infection
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Purpose: The spontaneous seroconversion rate of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) virus infection in children is lower than that in adults. However, few studies have investigated the rate of transition from the immune-tolerant to the early immune-clearance phase in children. Methods: From February 2000 to August 2011, we enrolled 133 children aged ＜18 years who had visited the Department of Pediatrics, Kyungpook National University Hospital. All subjects were in the immune-tolerant phase of HBeAg-positive CHB virus infection. The estimated transition rate into the early immune-clearance phase was calculated using the Kaplan-Meier method. Results: Among the 133 enrolled pediatric CHB virus infection patients in the HBeAg-positive immune-tolerant phase, only 21 children (15.8%) had converted to the early immune-clearance phase. The average age at entry into active hepatitis was 10.6±4.8 years. The incidence of transition from the immune-tolerant to the early immune-clearance phase in these children was 1.7 episodes/100 patient-years. When analyzed by age, the estimated transition rate was 4.6%, 7.1%, and 28.0% for patients aged ＜6, 6-12, ＞12 years, respectively. Conclusion: In children with CHB virus infection, the estimated rate of entry into the early immune-clearance phase was 28.0% for patients aged 12-18 years, which was significantly higher than that observed for children aged ＜12 years (11.7%; p=0.001).
Abstract
Purpose: The spontaneous seroconversion rate of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) virus infection in children is lower than that in adults. However, few studies have investigated the rate of transition from the immune-tolerant to the early immune-clearance phase in children. Methods: From February 2000 to August 2011, we enrolled 133 children aged ＜18 years who had visited the Department of Pediatrics, Kyungpook National University Hospital. All subjects were in the immune-tolerant phase of HBeAg-positive CHB virus infection. The estimated transition rate into the early immune-clearance phase was calculated using the Kaplan-Meier method. Results: Among the 133 enrolled pediatric CHB virus infection patients in the HBeAg-positive immune-tolerant phase, only 21 children (15.8%) had converted to the early immune-clearance phase. The average age at entry into active hepatitis was 10.6±4.8 years. The incidence of transition from the immune-tolerant to the early immune-clearance phase in these children was 1.7 episodes/100 patient-years. When analyzed by age, the estimated transition rate was 4.6%, 7.1%, and 28.0% for patients aged ＜6, 6-12, ＞12 years, respectively. Conclusion: In children with CHB virus infection, the estimated rate of entry into the early immune-clearance phase was 28.0% for patients aged 12-18 years, which was significantly higher than that observed for children aged ＜12 years (11.7%; p=0.001).
참고문헌 (18)
- Marx G, "Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins", J Infect Dis, 186, pp.295~301 (2002)
- McMahon BJ, "Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state", J Infect Dis, 151, pp.599~603 (1985)
- Chu CM, "Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma", J Gastroenterol Hepatol, 15, pp.E25~E30 (2000)
- Hsu YS, "Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B", Hepatology, 35, pp.1522~1527 (2002)
- Yoon JH, "Spontaneous HBeAg clearance rate and its affecting factors inpatients with chronic hepatitis B in Korea", Korean J Gastroenterol, 24, pp.1313~1319 (1992)
- Evans AA, "Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy", J Infect Dis, 176, pp.845~850 (1997)
- Lok AS, "A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children", Hepatology, 8, pp.1130~1133 (1988)
- Chang MH, "Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children", J Pediatr, 115, pp.385~390 (1989)
- 김유리아, "소아의 만성 B형 간염의 자연 경과", Korean Journal of Pediatrics, 47(3), pp.282~289 (2004), 대한소아과학회
- European Association for the Study of the Liver, "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update", Hepatol Int, 6, pp.531~561 (2012)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Shah U, "Management of chronic hepatitis B in children", J Pediatr Gastroenterol Nutr, 48 (2009)
- Choe BH, "Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better", J Pediatr Gastroenterol Nutr, 44, pp.92~98 (2007)
- Bortolotti F, "Long term effect of alpha interferon in children with chronic hepatitis B", Gut, 46, pp.715~718 (2000)
- Fujisawa T, "Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood", J Pediatr Gastroenterol Nutr, 30, pp.201~206 (2000)
- Bortolotti F, "Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study", Hepatology, 43, pp.556~562 (2006)
- Iorio R, "Long-term outcome in children with chronic hepatitis B: a 24-year observation period", Clin Infect Dis, 45, pp.943~949 (2007)